Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is JW Asset Management LLC’s 7th Largest Position

JW Asset Management LLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 26.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 413,392 shares of the biopharmaceutical company’s stock after selling 150,000 shares during the period. Catalyst Pharmaceuticals makes up approximately 4.0% of JW Asset Management LLC’s portfolio, making the stock its 7th largest position. JW Asset Management LLC owned about 0.35% of Catalyst Pharmaceuticals worth $6,949,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CPRX. Parkside Financial Bank & Trust acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $31,000. Nisa Investment Advisors LLC grew its position in Catalyst Pharmaceuticals by 306.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 3,829 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $123,000. PNC Financial Services Group Inc. grew its position in shares of Catalyst Pharmaceuticals by 42.5% in the third quarter. PNC Financial Services Group Inc. now owns 11,241 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 3,354 shares during the last quarter. Finally, CenterBook Partners LP grew its position in shares of Catalyst Pharmaceuticals by 20.0% in the third quarter. CenterBook Partners LP now owns 13,577 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 2,259 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CPRX has been the topic of several research reports. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Bank of America started coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They set a “buy” rating and a $23.00 price objective on the stock. HC Wainwright upped their price objective on shares of Catalyst Pharmaceuticals from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $34.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.71.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 25,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the sale, the insider now owns 124,433 shares in the company, valued at $2,045,678.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.00% of the stock is owned by insiders.

Catalyst Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ CPRX traded down $0.05 during midday trading on Friday, hitting $15.87. The stock had a trading volume of 601,618 shares, compared to its average volume of 1,392,920. The company has a fifty day moving average price of $15.68 and a 200 day moving average price of $15.00. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 29.52, a PEG ratio of 1.37 and a beta of 0.89. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.09 and a 1-year high of $17.50.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. The company had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. On average, research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.78 EPS for the current year.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.